CN115671160A - Probiotics and prebiotics composition with blood sugar reducing effect and application thereof - Google Patents
Probiotics and prebiotics composition with blood sugar reducing effect and application thereof Download PDFInfo
- Publication number
- CN115671160A CN115671160A CN202110852193.3A CN202110852193A CN115671160A CN 115671160 A CN115671160 A CN 115671160A CN 202110852193 A CN202110852193 A CN 202110852193A CN 115671160 A CN115671160 A CN 115671160A
- Authority
- CN
- China
- Prior art keywords
- probiotics
- powder
- parts
- prebiotics
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 48
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 44
- 239000008280 blood Substances 0.000 title abstract description 40
- 210000004369 blood Anatomy 0.000 title abstract description 40
- 230000001603 reducing effect Effects 0.000 title abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 48
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 19
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 19
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 19
- 229920001202 Inulin Polymers 0.000 claims abstract description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 11
- 229940029339 inulin Drugs 0.000 claims abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 11
- 230000000529 probiotic effect Effects 0.000 claims abstract description 11
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 10
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 7
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 7
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 7
- 240000005528 Arctium lappa Species 0.000 claims abstract 3
- 239000002775 capsule Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 244000046146 Pueraria lobata Species 0.000 claims description 2
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 19
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 241000222336 Ganoderma Species 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 9
- 241000186660 Lactobacillus Species 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000208843 Arctium Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000003416 Asparagus officinalis Species 0.000 description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- -1 granulating Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition of probiotics and prebiotics with the function of reducing blood sugar and application thereof, wherein the composition consists of the probiotics and the prebiotics, the probiotics comprise lactobacillus plantarum (Lactplantibibacillus plantarum) and lactobacillus acidophilus (Levictobacillus acidophilus), the preservation number of the lactobacillus plantarum is CGMCC 21895, the preservation number of the lactobacillus acidophilus is CGMCC21896, and the prebiotics comprise one or more of lucid ganoderma powder, cordyceps militaris powder, radix puerariae powder, burdock powder and inulin. The composition is reasonable in matching, not only provides rich and effective probiotic flora, but also matches nutrient substances required by growth and metabolism of probiotics, effectively promotes the field planting and propagation of the probiotics in human intestinal tracts, so that the structure of the intestinal flora is adjusted, the intestinal sugar metabolism and absorption process is optimized, the blood sugar level of people with diabetes is obviously reduced, and the life quality of patients is improved.
Description
Technical Field
The invention relates to the fields of health-care food and biomedicine, in particular to probiotics and a prebiotic composition with a blood sugar reducing effect and application thereof.
Background
With the improvement of living standard and the aggravation of aging of population, the number of patients with diabetes is increasing day by day. Diabetes has become a third type of chronic non-infectious disease that endangers human health following tumors, cardiovascular diseases. According to the world health organization and the international diabetes union, the total number of diabetes patients in the world reaches 3.66 hundred million by 2030. At present, chinese diabetic patients reach 1.298 billion and account for more than 1/3 of the patients all over the world, the adult diabetes prevalence rate is improved from 9.7% in 2010 to 12.8% in 2020, and the pre-adult disease proportion reaches 35.2%, and the data show that the number of the diabetes is rapidly increased year by year. Diabetes and its complications can not only directly bring the suffering of epidemic diseases and the threat of death to patients, but also bring serious economic difficulties to families and society. Therefore, there is a need to develop effective strategies for preventing and treating diabetes and related products.
Scientific research finds that the intestinal flora is closely related to diabetes. In one aspect, gut dysbacteriosis may contribute to the development and progression of diabetes. Unhealthy intestinal flora is the main culprit of diabetes caused by high-fat diet, and harmful metabolites of the intestinal flora, such as imidazole propionic acid, cause type 2 diabetes. On the other hand, healthy intestinal flora may be a secret recipe for treating diabetes. The genetic pattern of the intestinal flora is changed by adjusting the composition of the intestinal flora, so that the change of transcriptome, proteome and metabolome of the intestinal flora is achieved, the digestion, absorption and metabolic processes of a host are influenced to influence the glucose metabolism level of the host, and finally the blood sugar level of a diabetic patient is reduced and the immunity of the organism is improved.
The utilization of probiotics and/or prebiotics to regulate the intestinal flora and thus intervene and treat diabetes has become a research hotspot. Chinese patent (ZL 201610405159.0) discloses an asparagus fermented drink for improving intestinal function and a preparation method thereof, lactobacillus paracasei CICC6270 and lactobacillus paracasei CICC6271 are utilized for fermentation, the content and quality of water-soluble dietary fiber of asparagus are improved, and then prebiotics are added to realize synergistic interaction, so that the effect of improving the intestinal tract of an asparagus fermented product is greatly enhanced, and the combination of the prebiotics and the probiotics is proved to effectively regulate and improve the structure and function of intestinal flora. Chinese patent ZL201810073850.2 discloses a Lactobacillus plantarum DM-50 strain and application thereof, and the Lactobacillus plantarum is found to have the effect of reducing blood sugar through a gastric lavage test of diabetic mice, but the blood sugar reducing effect is not obvious. Chinese patent ZL201710820373.7 discloses a composition with an auxiliary blood sugar reducing function and a preparation method thereof, wherein the composition is prepared by extracting traditional Chinese medicines such as ginseng, scutellaria baicalensis and radix rehmanniae and then spraying the extracted traditional Chinese medicines into powder and mixing the powder in proportion, and has a certain auxiliary blood sugar reducing function, but the effect is slow and not obvious.
Although some of the prior publications show that probiotics or prebiotics have the effect of reducing blood sugar, related research reports are mostly limited to a single aspect, and some researches only focus on the probiotics, neglect the effect of nutrient substances (prebiotics) for maintaining the growth and metabolism of the probiotics, so that the bacteria are difficult to effectively colonize and continuously reproduce in the intestinal tract, and thus the efficacy of the probiotics cannot be effectively exerted. Some researches mainly focus on prebiotics, but the prebiotics and functional probiotics cannot be combined for research, and if only some nutrient substances are provided under the condition of not inoculating probiotics, the variety and the quantity of the probiotics cannot be ensured, and the regulation and control effect is only half the result.
Disclosure of Invention
In order to solve the existing problems, the invention provides a probiotic and prebiotic composition with the function of reducing blood sugar and application thereof.
The invention provides a composition of probiotics and prebiotics with the function of reducing blood sugar, which consists of two parts of probiotics and prebiotics, wherein the probiotics comprise lactobacillus plantarum (Lactplantibibacillus plantarum) with the strain number of ZKWD0907, which is preserved in China general microbiological culture Collection center (CGMCC 21895), the preservation date of 2021 year, 3 months and 11 days, the preservation address: the lactobacillus acidophilus strain of Beijing is ZKWD0906, is deposited in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms, has the preservation number of CGMCC21896, the preservation date of 2021, 3 months and 11 days, and the preservation address of: in Beijing, the prebiotics include one or more of Ganoderma powder, cordyceps powder, radix Puerariae powder, burdock powder, and inulin.
Optionally, in the composition: the probiotics comprise the following components in parts by weight: 1-6 parts of lactobacillus plantarum and 4-9 parts of lactobacillus acidificans.
Preferably, 3-5 parts of lactobacillus plantarum and 5-7 parts of lactobacillus fasuum.
Optionally, in the composition: the prebiotics comprise, by weight, 0-5 parts of ganoderma lucidum powder, 5-10 parts of cordyceps militaris powder, 0-3 parts of kudzu root powder, 0-3 parts of burdock powder and 2-5 parts of inulin, wherein the weight ratio of the cordyceps militaris powder to the inulin is 3-4:1.
preferably, the composition comprises the following components in parts by weight: 1-3 parts of probiotics and 2-5 parts of prebiotics.
It is another object of the present invention to provide granules, powders, capsules or tablets of the probiotic and prebiotic compositions in combination with a food/medically acceptable carrier.
It is a further object of the present invention to provide the use of said probiotic and prebiotic compositions in the manufacture of food, pharmaceutical and health care products.
Compared with the prior art, the invention has the positive and beneficial effects that:
the invention provides probiotics and a prebiotics composition with a hypoglycemic effect and application thereof. Through reasonable collocation of the probiotics and the prebiotics, the proportion among the probiotics, between the prebiotics and between the probiotics is adjusted, the respective effects of the probiotics and the prebiotics are fully exerted, so that the probiotics are better planted, reproduced and metabolized in intestinal tracts, the intestinal flora is effectively adjusted, the effect of reducing blood sugar by functional flora is fully exerted, and the purposes of quickly reducing blood sugar, stabilizing the blood sugar level and improving the life quality of diabetics are achieved. In addition, the composition also has the function of improving human immunity, and is suitable for wide range of people.
Detailed Description
The following examples are presented to further illustrate embodiments of the present invention, and it should be understood that the embodiments described herein are for purposes of illustration and explanation only and are not intended to limit the invention.
Example 1
Preparation of probiotic bacteria powder
1.1 preparation of Lactobacillus plantarum (Lactplantibibacillus plantarum ZKWD0907 CGMCC 21895) powder
Modified MRS culture medium (tryptone 20g, glucose 20g, beef extract 5g, yeast powder 5g, triammonium citrate 2g, sodium acetate 5g, tween 801mL, dipotassium hydrogen phosphate 2g, magnesium sulfate heptahydrate 0.2g, manganese sulfate monohydrate 0.05g, L-cysteine hydrochloride 1g, distilled water with constant volume to 1L, acetic acid with pH adjusted to 7.115 ℃ for steam sterilization), lactobacillus plantarum (Lactibacillus planterum ZKWD0907, preserved in China center for microbial cultures with preservation number CGMCC 21895) is inoculated with 5%, cultured at 37 ℃ for 24 hours under anaerobic seed number, OD600 is 1.201, centrifuged at 10000rpm for 10 minutes, defatted milk powder with mass percent of 10% is added into bacterial mud, and freeze-dried in a freeze-drying machine to obtain lactobacillus plantarum ZWD 0907 CC 95) bacterial powder with bacterial content of 100 hundred million/g.
1.2 preparation of powder of Lactobacillus acidofavorus (Levilactobacillus acidofiarinae ZKWD0906 CGMCC 21896)
Similar to the operation process of 1.1, modified MRS culture medium (tryptone 20g, glucose 20g, beef extract 5g, yeast powder 5g, triammonium citrate 2g, sodium acetate 5g, tween 801mL, dipotassium hydrogen phosphate 2g, magnesium sulfate heptahydrate 0.2g, manganese sulfate monohydrate 0.05g, L-cysteine hydrochloride 1g, distilled water to a constant volume of 1L, acetic acid to adjust pH to 7.115 ℃ for steam sterilization) is adopted, lactobacillus acidophilus (Levilactobacillus acidificiae ZKWD0906 is inoculated and preserved in a Chinese microbial strain preservation center with the preservation number of CGMCC 21896), the inoculation amount is 10%, anaerobic culture is carried out at 37 ℃ for 36 hours, OD600 is 1.362, 10000rpm is centrifuged for 10 minutes, skimmed milk powder with the mass percentage of 10% is added into bacterial mud, and freeze-drying is carried out in a freeze dryer, so that lactobacillus acidophilus (Levilactobacillus acidificiaificiaificianis KWD) is obtained, and the content of CGMCC 0906/218WD is 120 g.
Example 2
Probiotics and prebiotics composition A with blood sugar reducing effect
The freeze-dried fungus powder obtained in the embodiment 1.1-1.2 is weighed according to the weight ratio: lactobacillus plantarum (Lactplantibibacillus plantarum ZKWD0907 CGMCC 21895) 15g, and Lactobacillus acidificans (Levilactobacillus acidificarinae ZKWD0906 CGMCC 21896) 18g. Then weighing 6g of ganoderma lucidum powder (120 meshes), 30g of cordyceps militaris powder (100 meshes), 3g of burdock powder (100 meshes) and 15g of inulin (100 meshes) respectively.
The auxiliary materials comprise, by weight, 10 parts of glucose, 8 parts of edible essence, 5 parts of magnesium stearate and 5 parts of silicon dioxide.
And (3) fully mixing the materials, preparing granules, and bagging, wherein each bag contains 2g of the granules to obtain the prebiotics composition product A.
Example 3
Probiotics and prebiotics composition B with blood sugar reducing effect
The freeze-dried fungus powder obtained in the embodiment 1.1-1.2 is weighed according to the weight ratio: 3g of lactobacillus plantarum (Lactplantibacillus plantarum ZKWD0907 CGMCC 21895) and 12g of lactobacillus acidificans (Levilactobacillus acidifarninae ZKWD0906 CGMCC 21896). Then 22g of cordyceps militaris powder (100 meshes), 3g of pueraria powder (100 meshes) and 6g of inulin (100 meshes) are respectively weighed.
The auxiliary materials comprise, by weight, 10 parts of glucose, 8 parts of edible essence, 5 parts of magnesium stearate and 5 parts of silicon dioxide.
And (3) fully mixing the materials, granulating, finishing granules, and pressing into tablets, wherein each tablet is 0.25g, so that a prebiotic composition product B is obtained.
Example 4
Probiotics with blood sugar reducing effect and prebiotics composition C
The freeze-dried fungus powder obtained in the embodiment 1.1-1.2 is weighed according to the weight ratio: lactobacillus plantarum (Lactplantibibacillus plantarum ZKWD0907 CGMCC 21895) 22g, and Lactobacillus acidificans (Levilactobacillus acidificarinae ZKWD0906 CGMCC 21896) 15g. Then weighing 15g of ganoderma lucidum powder (100 meshes), 15g of cordyceps militaris powder (100 meshes), 9g of pueraria powder (100 meshes), 9g of burdock powder (100 meshes) and 7.5g of inulin (100 meshes) respectively.
And (3) fully mixing the weighed materials, and filling the mixture into starch capsules to prepare capsule products, wherein 0.5g of the starch capsules are prepared into the prebiotics composition product C.
Example 5
Probiotics with blood sugar reducing effect and prebiotics composition D
The freeze-dried fungus powder obtained in the embodiment 1.1-1.2 is weighed according to the weight ratio: lactobacillus plantarum (Lactplantibibacillus plantarum ZKWD0907 CGMCC 21895) 16.5g, and Lactobacillus acidificans (Levilactobacillus acidificarinae ZKWD0906 CGMCC 21896) 24.75g. Then 20g of cordyceps militaris powder (100 meshes) and 7.5g of inulin (100 meshes) are respectively weighed.
And (3) fully mixing the weighed materials, filling the mixture into starch capsules, and preparing capsule products, wherein 0.5g of each capsule is prepared to obtain a prebiotic composition product D.
Example 6
Test of hypoglycemic action of composition A on diabetes model mice
Selecting Kunming mouse, and male body weight 24-26g. Dose selection: the product of the composition A granules in example 2 is selected, the recommended amount of human body is 5 g/day/60 Kg-bw, the equivalent dose of mouse is 10 times of the recommended amount of human body, namely 0.83 g/Kg-bw is taken in daily, then 2 times and 3 times of low dose are respectively provided with a measuring group, namely 1.67 g/Kg-bw and 2.49 g/Kg-bw, distilled water is given to a control group, the composition A granules are subjected to equal volume intragastric administration once a day, and after 30 days of administration to the tested animal, various indexes are measured.
The experimental method comprises the following steps: influence on fasting plasma glucose of alloxan diabetes model mouse
After 24h of fasting, the animals are given 45mg/kg bw tetraoxypyrimidine through tail veins, on the 7 th day, fasting is carried out for 4h, blood glucose values are measured, and mice with blood glucose values of 10-25m mol/L are selected as hyperglycemia model mice. They were randomized into four groups, 1 model control group, 3 dose groups, with an average of 11 mice per group. The treatment groups were continuously administered with different concentrations of the test substance (composition A in example 2) for 30 days (distilled water was given to the control group), and fasting blood glucose values were measured 0.5h after the last gavage. The test data were statistically analyzed using t-test.
And (3) test results:
TABLE 1 Effect of the composition products of the present invention on fasting plasma glucose in the serum of hyperglycemic mice
As can be seen from table 1, the fasting blood glucose values of the mice in the medium-dose and high-dose groups were significantly lower than those of the model control group (P < 0.05) when the mice were orally administered with different doses of the composition a of example 2 for 30 days.
Example 7
Test of hypoglycemic Effect of the composition on diabetic patients
The test uses capsules prepared with sample composition D of example 5.
Subject selection: the condition of the patient is stable after the oral hypoglycemic drug is selected for treatment, the variety and the dosage of the drug do not need to be changed, and only adult type II diabetes patients with the maintenance dose are taken, and the fasting blood sugar is more than or equal to 7.8 mmol/l or the 2h postprandial blood sugar is more than or equal to 11.1 mmol/l. The subject has no complications such as heart, liver, kidney and the like, the liver and kidney function is good, and no glucocorticoid or other medicines influencing the blood sugar have been taken. The age of the subject is 18 years to 65 years, and the subjects are type II diabetes mellitus.
The test feeding method comprises the following steps: 80 subjects were randomly divided into two groups, and the type and dose of the hypoglycemic drug originally taken was unchanged, and the test group (test group) took capsules of composition D of example 5 2 times a day, 5 capsules each time. The control group was administered placebo in the same amount as the test diet. Each index was tested once at the beginning and end of the experiment.
And (4) judging the efficacy: the basic symptoms are obviously improved, and the blood sugar is effectively reduced by more than or equal to 10 percent compared with the blood sugar before treatment; no significant improvement in the basal symptoms was observed and a drop in blood glucose of <10% was considered ineffective.
And (3) test results: a total of 80 cases were observed. The composition is used for 22 men, 18 women, 42 years of youngest age, 64 years of youngest age, 54.6 years of average age, and 5.5 years of average course. In the control group, 14 men and 26 women were aged 40 years minimum and 65 years maximum, with a mean age of 54.9 years and a mean course of 5.8 years.
TABLE 2 fasting plasma glucose before and after meal and 2-hour postprandial plasma glucose content
( * P <0.05 for intra-group differential comparison; # for comparison of differences between treatment groups, P <0.05 )
TABLE 3 blood sugar level efficacy statistics
As can be seen from the results in Table 2, the fasting blood glucose of the test group decreased by 2.43 mmol/L on average, and the blood glucose decreased by 2.32 mmol/L on average after 2 hours. The fasting blood sugar and the blood sugar after 2 hours of the meal of the control group are not obviously reduced. Compared with the treatment groups, the fasting blood glucose value and the 2-hour postprandial blood glucose value of the test group are both obviously lower than the corresponding blood glucose value of the control group after one month.
The statistical results of blood sugar efficacy (table 3) show that the total effective rate of the test group reaches 80 percent, which is far higher than 15 percent of the control group.
The results show that the blood sugar level of the diabetics can be effectively reduced by taking the composition product of the patent.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various changes and modifications can be made without departing from the inventive concept of the present invention, and these changes and modifications are all within the scope of the present invention.
Claims (6)
1. A probiotic and prebiotic composition having hypoglycemic activity, characterized by: the composition comprises probiotics and prebiotics, wherein the probiotics comprise lactobacillus plantarum (Lactplatib lactobacillus plantarum) and lactobacillus acidophilus (Levilactobacillus acidifarinae), the preservation number of the lactobacillus plantarum is CGMCC 21895, the preservation number of the lactobacillus acidophilus is CGMCC21896, and the prebiotics comprise one or more of ganoderma lucidum powder, cordyceps militaris powder, radix puerariae powder, burdock powder and inulin.
2. A probiotic and prebiotic composition having a hypoglycemic effect according to claim 1 characterised in that: the probiotics comprise the following components in parts by weight: 1-6 parts of lactobacillus plantarum and 4-9 parts of lactobacillus plantarum.
3. A probiotic and prebiotic composition having a hypoglycemic effect according to claim 1 characterised in that: the prebiotics comprises the following components in parts by weight: 0-15 parts of ganoderma lucidum powder, 15-30 parts of cordyceps militaris powder, 0-9 parts of kudzu root powder, 0-9 parts of burdock powder and 6-15 parts of inulin, wherein the weight ratio of the cordyceps militaris powder to the inulin is (2-4): 1.
4. probiotic and prebiotic composition having a hypoglycemic effect according to claim 1, characterized in that: the probiotics and the prebiotics comprise the following components in parts by weight: 1-3 parts of probiotics and 2-5 parts of prebiotics.
5. A probiotic and prebiotic composition according to any of claims 1 to 4 formulated as a granule, powder, capsule or tablet in association with a food/medical acceptable carrier.
6. Use of a probiotic and prebiotic composition according to any of claims 1 to 4 in the manufacture of a food, pharmaceutical or health care product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110852193.3A CN115671160A (en) | 2021-07-27 | 2021-07-27 | Probiotics and prebiotics composition with blood sugar reducing effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110852193.3A CN115671160A (en) | 2021-07-27 | 2021-07-27 | Probiotics and prebiotics composition with blood sugar reducing effect and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671160A true CN115671160A (en) | 2023-02-03 |
Family
ID=85058966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110852193.3A Pending CN115671160A (en) | 2021-07-27 | 2021-07-27 | Probiotics and prebiotics composition with blood sugar reducing effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671160A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179328A (en) * | 1997-11-14 | 1998-04-22 | 王辉 | Medicine and food for treating diabetes and producing method thereof |
| CN101305795A (en) * | 2007-05-17 | 2008-11-19 | 沙纯荣 | Chinese caterpillar fungus powder and productive technology thereof |
| CN103656076A (en) * | 2013-12-18 | 2014-03-26 | 南昌大学 | Probiotics and Chinese herbal medicine compound preparation with hypoglycemic function |
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
-
2021
- 2021-07-27 CN CN202110852193.3A patent/CN115671160A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179328A (en) * | 1997-11-14 | 1998-04-22 | 王辉 | Medicine and food for treating diabetes and producing method thereof |
| CN101305795A (en) * | 2007-05-17 | 2008-11-19 | 沙纯荣 | Chinese caterpillar fungus powder and productive technology thereof |
| CN103656076A (en) * | 2013-12-18 | 2014-03-26 | 南昌大学 | Probiotics and Chinese herbal medicine compound preparation with hypoglycemic function |
| CN105105145A (en) * | 2015-09-14 | 2015-12-02 | 吉林省农业科学院 | Lactobacillus plantarum and application thereof in preparing functional food for reducing blood glucose and blood fat |
Non-Patent Citations (3)
| Title |
|---|
| 郑晓卫;沈雪梅;张子剑;刘杨柳;董志忠;陈博;: "益生菌在血糖调控中的研究进展", 中国微生态学杂志, no. 02, pages 222 - 228 * |
| 阮芳铭, 赵岚, 周昌艳, 郭俊生, 杨焱, 贾薇, 季红光, 郭苗莉, 俞云亮: "食药两用菌及植物对实验性糖尿病小鼠血糖的影响", 解放军预防医学杂志, no. 05, pages 327 - 330 * |
| 陈兴都;陈庆安;翟丹云;赵莉莉;丁心顺;董延虎;: "菊粉果聚糖的保健功能及应用价值", 中国酿造, no. 01, pages 327 - 330 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104922586B (en) | A kind of preparation and its application of the probiotics fermention Chinese medicine preparation for preventing chicken coccidiasis | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN109528814B (en) | Microecological preparation of lactobacillus fermented astragalus membranaceus as well as preparation method and application of microecological preparation | |
| JP2018153182A (en) | Lactobacillus plantarum tci378, and use thereof in reducing fat and improving gastrointestinal function | |
| CN112263669A (en) | Oligopeptide traditional Chinese medicine probiotic compound for relieving hyperuricemia | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN116891810A (en) | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation | |
| CN113755370B (en) | Application of lactobacillus acidophilus LA85 in preparation of hypolipidemic drugs or health-care foods | |
| CN105661515A (en) | Enzyme lozenges for three-hypers and preparation method thereof | |
| CN114452308B (en) | Probiotics protective agent, and microecological preparation prepared from same and application thereof | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN103932180B (en) | A kind ofly to release the pressure and the health food of antifatigue and two-step fermentation preparation method thereof | |
| CN108618128A (en) | Adjust the composition and its preparation method and application of immunity | |
| KR101076223B1 (en) | Composition for treating and preventing obesity or hyperlipidemia comprising fermented oriental herb | |
| KR20090092743A (en) | Composition for alleviation of alcohol-induced hangover comprising lactic acid bacteria fermented Ssangwhatang | |
| CN110384240A (en) | Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application | |
| CN101297820A (en) | Streptococcus faecium function signal molecule formulation and product thereof for reducing fat and slimming | |
| CN115671160A (en) | Probiotics and prebiotics composition with blood sugar reducing effect and application thereof | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of | |
| CN112690456A (en) | Preparation method and application of animal bifidobacterium F1-7 and krill oil composition for improving atherosclerosis inflammation | |
| CN112336754B (en) | Application of cladosporium compound microbial inoculum in preparation of medicines for treating metabolic diseases and culture method | |
| CN107699501A (en) | A kind of culture medium of Hericium erinaceus, bioconversion mycelium, the mycelial extract of bioconversion and application thereof | |
| CN109619586A (en) | A kind of peony seed oil blood fat reducing preparation and preparation method thereof | |
| CN108524749A (en) | A kind of Chinese medicine composition and application for improving intestinal flora distribution | |
| CN115282185B (en) | Fermented salvia miltiorrhiza extract containing salvia miltiorrhiza enzymes, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |